Molecular Monitoring in CML and ALL
This information was originally presented on September 20, 2013, at the NCCN 8th Annual Congress: Hematologic Malignancies™ held in New York, New York.
This activity is designed to meet the educational needs of hematologists, oncologists, nurses, pharmacists, and other health care professionals who manage patients with hematologic malignancies.
Following this activity, participants should be able to:
- Describe the clinical evidence regarding the prognostic significance of early molecular response to TKI therapy and the significance of molecular monitoring in patients with CML
- Recognize the significance of molecular monitoring in patients with ALL
Neil P. Shah, MD, PhD
UCSF Helen Diller Family Comprehensive Cancer Center
- 0.50 Participation
- 0.60 Nurse
- 0.50 Pharmacist
- 0.50 Physician